The conversation Dr. Jitesh Patel keeps having in his Snellville exam room goes something like this. A patient, often in their sixties or seventies, sits across from him with the imaging from their recent CT scan pulled up on the monitor between them. There is a small mass on one of their kidneys. Three centimeters or less. Solid, contained, treatable. The kind of finding that two decades ago would have led directly to a conversation about partial nephrectomy and the recovery curve that follows it.
These days the conversation is different. The patient has usually done their own research before walking in. They have read about histotripsy on a news site, watched a video about its first FDA clearance for liver tumors, maybe seen a post in a kidney cancer support group from someone in another state who got into a clinical trial. They want to know whether the same approach could apply to them, and whether the scalpel is still the right answer for what is on the screen.
Dr. Patel, the founder and president of Advanced Urology, has been thinking about that question for longer than most of his peers. In early April, his practice publicly announced that it is bringing histotripsy to Atlanta, becoming the first urology practice in the city to install the technology for kidney cancer applications. Advanced Urology runs 13 clinics and 6 surgery centers across Georgia, and the histotripsy program will operate out of its surgical platform. The announcement landed quietly in the national press. Inside the urology community, it landed harder.
A Different Category of Treatment
Histotripsy is not an incremental improvement over existing treatments. It is something genuinely new. The technology uses precisely focused, high-frequency ultrasound pulses to generate microscopic cavitation bubbles inside a tumor. The bubbles expand and collapse rapidly, mechanically liquefying the cancer cells from the inside out, while leaving surrounding blood vessels, healthy tissue, and the kidney's delicate collecting system intact. There are no incisions, no thermal energy, no radiation. The body resorbs the liquefied tissue on its own.
The FDA cleared histotripsy for liver tumors in October 2023, based on data from the HOPE4LIVER trials. The kidney indication is still investigational. The pivotal HOPE4KIDNEY trial, which enrolled 67 patients across 15 US sites, completed enrollment in mid 2025. Patients will be followed for five years, with full trial completion anticipated in 2030. The data is intended to support FDA regulatory clearance for the kidney application.
For urologists who have spent careers refining the surgical and thermal ablative techniques that currently define kidney cancer care, that mechanism is a problem worth taking seriously. Cryoablation, radiofrequency ablation, and microwave ablation all rely on heat or cold to destroy tumor tissue, and all of them carry some risk of collateral damage to the structures around the tumor. Histotripsy, in contrast, produces sharply demarcated lesions while leaving blood vessels and the collecting system intact. For a urologist looking at a vascular organ with intricate architecture, that precision is the part that matters.
"The scalpel is not going away. But for a growing number of patients, it is going to become one option among several."
The Strategy Behind the Announcement
The technology itself is being studied at academic medical centers across the country, so that part of the story is not new. What is new is that a private specialty practice in suburban Atlanta has decided to commit to it now, before the kidney indication has cleared and before the long-term data has matured. Most practices will wait. There is nothing wrong with waiting. The patients enrolled in HOPE4KIDNEY are the ones generating the evidence that will eventually make broader adoption possible, and the prudent move for any urologist is to let that evidence accumulate before changing the standard of care.
Dr. Patel chose to move now. Talking to colleagues, he frames the decision as a strategic one rather than a clinical one. Advanced Urology has spent years building a platform that includes 13 clinics, 6 surgery centers, subspecialty trained urologists, advanced molecular testing, and a data infrastructure that tracks more than 100 million data points across the practice's patient population. None of that infrastructure justifies itself unless the practice can absorb new categories of treatment quickly when they arrive. Histotripsy is the test of whether the platform actually does what it was built to do.
Dr. Dev Mally, the practice's Chief Physician Officer, framed it in similar terms when the launch was announced. "As clinicians, we have always asked ourselves whether we can do better for our patients," Mally said in the practice's announcement. "Less invasive, fewer side effects, faster recovery, and outcomes that hold up over time. Histotripsy answers that question in kidney cancer. This is precisely the kind of innovation our Centers of Excellence were built to deliver."
Dr. Patel has been more direct about the strategic dimension. "Our patients deserve the world's best care, not just Atlanta's best," he said in the announcement. "Histotripsy is a once in a generation leap, and we're bringing it home."
The Infrastructure Question
Physicians who have brought emerging technologies into community practice will tell you that the equipment is the easy part. The hard part is everything around it. Training. Protocols. Patient selection criteria. The coordination between urology, interventional imaging, and oncology that has to happen for every case. The patient education materials, the consultation workflow, the consent process, the long-term follow up that runs for years. None of that work shows up in the press release. None of it is visible from outside the practice. It is also the only thing that determines whether a new technology actually delivers on its promise once patients start walking in the door.
Patient selection is the part that matters most for histotripsy right now, and the part Dr. Patel has been most careful about in public. The technology has working ranges. Tumor size, location, the imaging window, proximity to other structures, all of it factors into whether a given patient is a candidate. Marketing the procedure aggressively without the clinical judgment to identify the right patients does more harm than good, and Dr. Patel has been deliberate about drawing that line in conversations with referring physicians.
In the practice's own announcement, the candidate profile is narrower than the headlines suggest. Histotripsy for kidney tumors is currently most applicable to patients with small, solid, non-metastatic renal masses, typically three centimeters or smaller, who are appropriate for active treatment but may not be ideal surgical candidates due to age, comorbidities, or reduced kidney function. For most patients with a treatable kidney mass, partial nephrectomy is still the gold standard. Dr. Patel says so plainly. The established surgical pathway is the right answer for the majority of cases in 2026, and histotripsy is an emerging option for the patients on the margins of that majority.
"The equipment is the easy part. The hard part is everything around it."
What Comes Next
The bigger question hovering over Advanced Urology's decision is who else in the field will follow. Histotripsy is currently being deployed primarily through interventional radiology departments at academic medical centers, partly an accident of where the equipment was first installed and partly a function of the imaging-heavy workflow. But the patients with these tumors are urology patients. They come through urology referral pathways, they have urologic follow up, and they get managed long term by urologists. Who actually performs the procedure, and who owns the patient relationship through the years of surveillance that follow, has not been settled.
Practices that organize themselves around the technology early are likely to set the answer. Dr. Patel is convinced that institutional readiness, the kind that takes years to build and is invisible until the moment it gets used, will matter more than any single piece of equipment. He also believes patients will reward practices that move early, prepare carefully, and stay honest about what the evidence does and does not yet show.
Whether histotripsy turns into a niche tool or a mainstream first-line option for small renal masses depends on what HOPE4KIDNEY produces over the next several years. The urologists watching most closely are the ones already working out how to integrate it. For patients in metro Atlanta facing a kidney cancer diagnosis, that conversation is no longer happening in a clinic several states away. It is happening in Snellville.
About Advanced Urology
Advanced Urology is a leading, patient-centered urology practice serving the Atlanta area with 13 clinic locations and 6 AAAHC accredited state-of-the-art ambulatory surgery centers. As a true one-stop shop for urologic care, we deliver fully integrated services including Advanced Focal Therapy Programs for genitourinary (GU) cancers, Interventional Radiology (IR), Patient Navigation Programs, Advanced Imaging with PET / CT, and an Advanced Cancer Care Center that provides innovative care and therapies for advanced stage cancers including access to an in-office dispensary, all under one coordinated model.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission.
